C14orf104 Inhibitors
The functional activity of the protein C14orf104 can be attenuated by a diverse array of chemical inhibitors which target various biochemical and cellular pathways. For instance, chemical compounds that interfere with histone deacetylation processes could indirectly suppress the expression of C14orf104 by modifying the chromatin architecture, limiting the interaction between transcription factors and the C14orf104 gene. Similarly, compounds that inhibit the mTOR signaling pathway could exert a downstream effect that diminishes the general protein synthesis mechanism, consequently reducing the production of C14orf104. Additionally, by obstructing PI3K/Akt and MAPK/ERK pathways with specific inhibitors, there could be a decrease in the stability and translation of C14orf104 due to altered regulatory protein activities which are crucial for the maintenance of C14orf104.
Inhibitors that target receptor tyrosine kinases like EGFR may also play a role in modulating the turnover and localization of C14orf104 by affecting related signaling pathways. Interruptions in the cell cycle through the inhibition of kinases responsible for cell division may alter the expression levels of proteins, including C14orf104. Furthermore, disrupting calcium signaling by inhibiting calcium pumps can lead to a wide-ranging impact on cell function and indirectly impinge upon the activity of C14orf104. Lastly, inhibition of glycolysis and proteasome activity could lead to decreased energy availability and increased protein degradation stress, respectively, both of which could contribute to lower levels of C14orf104.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor which would lead to hyperacetylation of histones, potentially altering the chromatin structure and thereby decreasing the accessibility of transcription factors to the C14orf104 gene, resulting in reduced C14orf104 protein levels. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor that would lead to deactivation of downstream signaling pathways, reducing the translation of the C14orf104 protein as part of a broader inhibition of protein synthesis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor that would block the PI3K/Akt signaling pathway, reducing the stability or translation of the C14orf104 protein by affecting pathways that control protein synthesis and degradation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor that would block the MAPK/ERK pathway, altering the phosphorylation state and function of proteins that regulate the stability and function of the C14orf104 protein. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
EGFR inhibitor that would prevent downstream signaling involved in maintaining the stability or localization of the C14orf104 protein within the cell. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
Aurora kinase inhibitor that might disrupt cell cycle progression, affecting the turnover or expression level of the C14orf104 protein. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
SERCA pump inhibitor that leads to increased cytosolic calcium levels and can affect numerous signaling pathways, impacting the stability or activity of the C14orf104 protein indirectly. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
TGF-β receptor kinase inhibitor which may alter the SMAD signaling pathways, affecting downstream targets including the C14orf104 protein. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
EGFR tyrosine kinase inhibitor that could indirectly affect the turnover or activity of the C14orf104 protein by modulating EGFR-dependent signaling pathways. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
Glycolysis inhibitor that would decrease energy production, affecting the energy-dependent processes that control the synthesis or degradation of the C14orf104 protein. | ||||||